<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201796</url>
  </required_header>
  <id_info>
    <org_study_id>027IC13250</org_study_id>
    <secondary_id>2014-003757-33</secondary_id>
    <nct_id>NCT03201796</nct_id>
  </id_info>
  <brief_title>Prulifloxacin in Chronic Bacterial Prostatitis (CBP)</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hippocrates Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy and safety of prulifloxacin in comparison to
      levofloxacin in the treatment of patients affected by CBP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, levofloxacin controlled, parallel group, multicentre,
      international, prospective study. The patients will be enrolled in the study and will be
      randomized to prulifloxacin or levofloxacin. Patient enrolment will be competitive.

      The present study is planned to verify the microbiological and the clinical efficacy of a
      28-day treatment period with prulifloxacin 600 mg in comparison with 28-day treatment period
      with levofloxacin 500 mg, both administered once daily, in patients with CBP. Safety and
      tolerability of a 28-day treatment period with prulifloxacin 600 mg will be also evaluated in
      comparison to levofloxacin 500 mg.

      Levofloxacin 500 mg tablets has been selected as treatment comparator because it represents
      the drug of choice authorised for the treatment of CBP. Consequently, the dosage regimen to
      be administered to the patients is consistent with that reported in the relevant SPC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, levofloxacin controlled, multicentre, international, prospective study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The present study will be performed in double blind condition. Consequently, during the study, neither the Investigator nor the patient will be aware of the treatment assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication of bacterial growth</measure>
    <time_frame>7 days after the EOT</time_frame>
    <description>Eradication defined as absence of bacterial growth as &lt;10^2 CFU/ml in voided bladder 3 (VB3) or expressed prostatic secretion (EPS) after 7 days from the End Of Treatment (EOT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication of bacterial growth</measure>
    <time_frame>3 months after the EOT</time_frame>
    <description>Eradication defined as absence of bacterial growth as &lt;10^2 CFU/ml in voided bladder 3 (VB3) or expressed prostatic secretion (EPS) after 3 months from the EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of bacterial growth</measure>
    <time_frame>6 months after the EOT</time_frame>
    <description>Eradication defined as absence of bacterial growth as &lt;10^2 CFU/ml in voided bladder 3 (VB3) or expressed prostatic secretion (EPS) after 6 months from the EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in National Institute of Health - Chronic Prostatitis Symptom (NIH-CPSI)</measure>
    <time_frame>Screening - 7 days after the EOT</time_frame>
    <description>Reduction of total score in NIH-CPSI after 7 days from the EOT in comparison to the screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in National Institute of Health - Chronic Prostatitis Symptom (NIH-CPSI)</measure>
    <time_frame>Screening - 3 months after the EOT</time_frame>
    <description>Reduction of total score in NIH-CPSI after 3 months from the EOT in comparison to the screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in National Institute of Health - Chronic Prostatitis Symptom (NIH-CPSI)</measure>
    <time_frame>Screening - 6 months after the EOT</time_frame>
    <description>Reduction of total score in NIH-CPSI after 6 months from the EOT in comparison to the screening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-related adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Monitoring of the frequency of adverse events, physical examination, vital signs, ECG, laboratory analyses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Chronic Bacterial Prostatitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prulifloxacin 600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prulifloxacin 600 mg</intervention_name>
    <description>Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Unidrox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500mg</intervention_name>
    <description>Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Levoxacin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male between 18 and 50 years of age (limited included) with no limitation of race.

          2. Patients presenting symptoms of prostatitis for at least 3 months.

          3. Laboratory evidence of CBP at Visit 0 (Screening), assessed by

             Meares&amp;Stamey fourglass test and defined as:

               1. VB3 or EPS specimen containing ≥10^2 colony-forming units/ml of pathogen/s if the
                  VB2 specimen is sterile; or

               2. VB3 or EPS specimen containing ≥10^2 colony-forming units/ml of pathogen/s
                  different from any present in the VB2.

          4. Medications for chronic prostatitis and/or medications that may affect bladder or
             prostate function (including but not limited to hormone therapy, anticholinergic or
             alpha blocker) must be discontinued at least 7 days before study drug intake.

          5. Patients legally capable to give their consent to participate the study, and available
             to sign and date the written informed consent.

        Exclusion Criteria:

          1. Known hypersensitivity or allergy to antibacterial fluoroquinolones or to any
             components of the study medications.

          2. Pathogen/s resistant to the study drugs at Visit 0 (Screening).

          3. Suspicion for prostatic cancer, neurogenic bladder, Benign Prostatic Hypertrophy
             (BPH), bladder neck obstruction or urethral stricture.

          4. Body Mass Index (BMI) &lt; 16 kg/m^2.

          5. Immunocompromised patients.

          6. Signs or symptoms or clinical documentation for concurrent infections (including but
             not limited to sexually transmitted infections) and/or neoplasm.

          7. Clinically significant abnormalities on physical examination, vital signs, ECG,
             laboratory tests at Visit 0 (Screening Visit).

          8. Significant liver disease, defined as known active hepatitis or elevated liver enzymes
             &gt; 3 times the upper boundary of the normal ranges.

          9. Value of creatinine outside the normal ranges and judged clinically relevant by
             Investigator.

         10. History of cardiac disease, including but not limited to myocardial infarction, heart
             failure, cardiomyopathy, cardiac hypertrophy, cardiac arrhythmias, bradycardia,
             cardiac conduction abnormalities, long QT syndrome.

         11. Value of electrolytes (sodium, potassium, calcium, magnesium, chloride) outside the
             normal ranges and judged clinically relevant by Investigator.

         12. Patients under treatment with medications that may cause increase of the QT interval.

         13. History of tendinopathy.

         14. Patients with latent or known deficiencies for the glucose-6-phosphate dehydrogenase,
             or with hereditary problems of galactose intolerance or the Lapp lactase deficiency or
             glucose-galactose malabsorption.

         15. Recent or past history of psychiatric illness or epilepsy.

         16. Treatment with antibiotics or antibacterials within 2 weeks before study drug start
             intake.

         17. Treatment with experimental drugs (prulifloxacin or levofloxacin) or other
             fluoroquinolones within 4 weeks before study drug start intake.

         18. Diabetic patients in treatment with oral hypoglycemic drugs and insulin.

         19. Patients under treatment with corticosteroids or Non-Steroidal Antiflammatory Drugs
             (NSAIDs).

         20. Concomitant treatment with xanthines or anticoagulant drugs or drugs producing
             hypokalemia or diuretics.

         21. Positive history for drugs and alcohol abuse.

         22. Inability to comply with the protocol requirements, instructions or study-related
             restrictions (i.e. uncooperative attitude, inability to return for study-visits,
             improbability of completing the clinical study).

         23. Vulnerable subjects (i.e. persons kept in detention).

         24. Subject involved in the conduct of the study (i.e. Investigator or his/her deputy,
             first grade relatives, pharmacist, assistant or other personnel).

         25. Participation to an interventional clinical trial within 3 months prior to Visit 0
             (Screening Visit).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Lipone</last_name>
    <phone>+ 39 06 91045349</phone>
    <email>p.lipone@angelini.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Del Vecchio</last_name>
    <phone>+ 39 06 91045311</phone>
    <email>a.delvecchio@angelini.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology Clinic General Hospital of Athens &quot;GENNIMATAS&quot;</name>
      <address>
        <city>Athens</city>
        <zip>15669</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Gkialas, MD</last_name>
      <phone>(+) 30 2107768328</phone>
      <email>giangkialas@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Ioannis Gkialas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Department General Hospital of Piraeus &quot;TZANEIO&quot;</name>
      <address>
        <city>Piraeus</city>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Stamatiou, MD</last_name>
      <phone>(+) 30 6934917578</phone>
      <email>stamatiouk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Konstantinos Stamatiou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Urologia- Azienda Ospedaliera San Giuseppe Moscati</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virgilio Cicalese, MD</last_name>
      <phone>0825 203384</phone>
      <email>vicicalese@aosgmoscati.av.it</email>
    </contact>
    <investigator>
      <last_name>Virgilio Cicalese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Dipartimento della Donna, del bambino e delle malattie urologiche - Azienda ospedaliero- Universitaria e Policlinico di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio Brunocilla, MD</last_name>
      <phone>+39 015 2142374</phone>
      <email>eugenio.brunocilla@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Eugenio Brunocilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologia- Azienda Ospedaliero - Universitaria &quot;Policlinico - Vittorio Emanuele&quot;</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Morgia, MD</last_name>
      <phone>095 378 2373</phone>
      <email>gmorgia@policlinico.unict.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Morgia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Urologica- Azienda Ospedaliero Universitaria Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocco Damiano, MD</last_name>
      <phone>0961 364.7219</phone>
      <email>damiano@unicz.it</email>
    </contact>
    <investigator>
      <last_name>Rocco Damiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Careggi&quot;</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Carini, MD</last_name>
      <phone>055 2758011</phone>
      <email>marco.carini@unifi.it</email>
    </contact>
    <investigator>
      <last_name>Marco Carini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;Federico II&quot;- Dip. Di Ostreticia, ginecologia, Urologia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Mirone, MD</last_name>
      <phone>+39 081 746 2611</phone>
      <email>mirone@unina.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Mirone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Urologica del Dipartimento di Scienze Chirurgiche- Policlinico Universitario Agostino Gemelli di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Sacco, MD</last_name>
      <phone>0630155290</phone>
      <email>emilio.sacco@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Emilio Sacco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Urologia- AO &quot;Città della Salute e della Scienza&quot; di Torino - OSP.S. GIOV.BATTISTA MOLINETTE</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Gontero, MD</last_name>
      <phone>0116706518</phone>
      <email>paolo.gontero@unito.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Gontero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urologia- Ospedale di Trento- Presidio ospedaliero S. Chiara - Azienda Provinciale per i servizi sanitari (APSS)</name>
      <address>
        <city>Trento</city>
        <zip>38123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tommaso CAI, MD</last_name>
      <email>tommaso.cai@apss.tn.it</email>
    </contact>
    <investigator>
      <last_name>Tommaso Cai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.angelinipharma.com</url>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacterial prostatitis</keyword>
  <keyword>CBP</keyword>
  <keyword>Levofloxacin</keyword>
  <keyword>Prulifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Prulifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

